QQQ   427.32 (-0.75%)
AAPL   181.56 (-0.41%)
MSFT   402.79 (-0.31%)
META   471.75 (-0.33%)
GOOGL   141.12 (+0.43%)
AMZN   167.08 (-1.43%)
TSLA   193.76 (-3.10%)
NVDA   694.52 (-4.35%)
NIO   5.96 (-2.93%)
AMD   165.69 (-4.70%)
BABA   73.15 (-1.03%)
T   16.92 (-0.29%)
F   12.26 (-0.33%)
MU   80.71 (+1.52%)
CGC   3.54 (-7.33%)
GE   148.62 (-0.36%)
DIS   109.44 (-1.94%)
AMC   4.67 (-3.52%)
PFE   27.60 (-0.07%)
PYPL   58.63 (-0.86%)
XOM   102.75 (-0.94%)
QQQ   427.32 (-0.75%)
AAPL   181.56 (-0.41%)
MSFT   402.79 (-0.31%)
META   471.75 (-0.33%)
GOOGL   141.12 (+0.43%)
AMZN   167.08 (-1.43%)
TSLA   193.76 (-3.10%)
NVDA   694.52 (-4.35%)
NIO   5.96 (-2.93%)
AMD   165.69 (-4.70%)
BABA   73.15 (-1.03%)
T   16.92 (-0.29%)
F   12.26 (-0.33%)
MU   80.71 (+1.52%)
CGC   3.54 (-7.33%)
GE   148.62 (-0.36%)
DIS   109.44 (-1.94%)
AMC   4.67 (-3.52%)
PFE   27.60 (-0.07%)
PYPL   58.63 (-0.86%)
XOM   102.75 (-0.94%)
QQQ   427.32 (-0.75%)
AAPL   181.56 (-0.41%)
MSFT   402.79 (-0.31%)
META   471.75 (-0.33%)
GOOGL   141.12 (+0.43%)
AMZN   167.08 (-1.43%)
TSLA   193.76 (-3.10%)
NVDA   694.52 (-4.35%)
NIO   5.96 (-2.93%)
AMD   165.69 (-4.70%)
BABA   73.15 (-1.03%)
T   16.92 (-0.29%)
F   12.26 (-0.33%)
MU   80.71 (+1.52%)
CGC   3.54 (-7.33%)
GE   148.62 (-0.36%)
DIS   109.44 (-1.94%)
AMC   4.67 (-3.52%)
PFE   27.60 (-0.07%)
PYPL   58.63 (-0.86%)
XOM   102.75 (-0.94%)
QQQ   427.32 (-0.75%)
AAPL   181.56 (-0.41%)
MSFT   402.79 (-0.31%)
META   471.75 (-0.33%)
GOOGL   141.12 (+0.43%)
AMZN   167.08 (-1.43%)
TSLA   193.76 (-3.10%)
NVDA   694.52 (-4.35%)
NIO   5.96 (-2.93%)
AMD   165.69 (-4.70%)
BABA   73.15 (-1.03%)
T   16.92 (-0.29%)
F   12.26 (-0.33%)
MU   80.71 (+1.52%)
CGC   3.54 (-7.33%)
GE   148.62 (-0.36%)
DIS   109.44 (-1.94%)
AMC   4.67 (-3.52%)
PFE   27.60 (-0.07%)
PYPL   58.63 (-0.86%)
XOM   102.75 (-0.94%)
LON:GNS

Genus (GNS) Share Price, News & Analysis

GBX 1,850
+26.00 (+1.43%)
(As of 02/20/2024 ET)
Today's Range
1,790
1,853
50-Day Range
1,780
2,354
52-Week Range
1,478
3,178
Volume
79,944 shs
Average Volume
90,810 shs
Market Capitalization
£1.22 billion
P/E Ratio
3,627.45
Dividend Yield
1.73%
Price Target
GBX 4,500

Genus MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
143.2% Upside
GBX 4,500 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.14mentions of Genus in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.98 out of 5 stars


GNS stock logo

About Genus Stock (LON:GNS)

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.

GNS Stock Price History

GNS Stock News Headlines

Estimating The Intrinsic Value Of Genus plc (LON:GNS)
Jeff Bezos Backs "Drug Smuggler" to Fight Alzheimer's
A small, publicly traded biotech is racing to the discovery of a lifetime: Using a Drug Smuggler to Fight Alzheimer's, Parkinson's and Dementia. This radical treatment is so promising, Biogen, Sanofi and Genentech paid $1 billion to license it. Click here to learn more >>>
Genus (LON:GNS) Reaches New 12-Month Low at $1,650.00
Genus PLC
Genus PLC GNS
The perfect AI stock under $10
Normally, bringing a new drug to market takes an average of 10 years and between $2.5 and $12 billion. However, new AI technology has the potential to make the process up to 1000 times faster. This #1 AI company is at the forefront of it all.
A Look At The Fair Value Of Genus plc (LON:GNS)
Genus plc (GNS.L)
Genus' (LON:GNS) Dividend Will Be £0.217
Genus (LON:GNS) Will Pay A Dividend Of £0.217
See More Headlines
Receive GNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 12/8 Dividend
11/09/2023
Dividend Payable
12/08/2023
Today
2/20/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
3,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 4,500
High Stock Price Target
GBX 4,500
Low Stock Price Target
GBX 4,500
Potential Upside/Downside
+144.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
£33.30 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£689.70 million
Cash Flow
GBX 36.45 per share
Book Value
GBX 877 per share

Miscellaneous

Free Float
N/A
Market Cap
£1.22 billion
Optionable
Not Optionable
Beta
0.34
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Jorgen Kokke (Age 56)
    Chief Executive Officer & Director
    Comp: $578.87k
  • Ms. Alison Jane Henriksen ACA (Age 57)
    CFO & Executive Director
    Comp: $605k
  • Dr. Matt Culbertson
    Chief Operating Officer
  • Dr. Elena Rice
    Head of R&D and Chief Scientific Officer
  • Mr. Daniel William David Hartley
    Group General Counsel & Company Secretary
  • Ms. Angelle R. Rosata
    Group Human Resources Director
  • Mr. Jerry Thompson
    Chief Operating Officer of Genus ABS Beef
  • Dr. Nate Zwald
    Chief Operating Officer of Genus ABS Dairy
  • Andrew Thompson
    Head of ABS EMEA
  • Ms. Janet Duane
    Group Financial Controller














GNS Stock Analysis - Frequently Asked Questions

Should I buy or sell Genus stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genus in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GNS shares.
View GNS analyst ratings
or view top-rated stocks.

What is Genus' stock price target for 2024?

1 equities research analysts have issued 12-month price targets for Genus' stock. Their GNS share price targets range from GBX 4,500 to GBX 4,500. On average, they expect the company's share price to reach GBX 4,500 in the next year. This suggests a possible upside of 143.2% from the stock's current price.
View analysts price targets for GNS
or view top-rated stocks among Wall Street analysts.

How have GNS shares performed in 2024?

Genus' stock was trading at GBX 2,170 at the start of the year. Since then, GNS shares have decreased by 14.7% and is now trading at GBX 1,850.
View the best growth stocks for 2024 here
.

How often does Genus pay dividends? What is the dividend yield for Genus?

Genus announced a dividend on Thursday, September 7th. Stockholders of record on Thursday, November 9th will be given a dividend of GBX 21.70 per share on Friday, December 8th. This represents a dividend yield of 0.97%. The ex-dividend date is Thursday, November 9th. This is a positive change from the stock's previous dividend of GBX 10.30. The official announcement can be viewed at this link.
Read our dividend analysis for GNS
.

Is Genus a good dividend stock?

Genus (LON:GNS) pays an annual dividend of GBX 32 per share and currently has a dividend yield of 1.48%. The dividend payout ratio is 6,274.51%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for GNS.

What other stocks do shareholders of Genus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genus investors own include Clinigen Group (CLIN), Glencore (GLEN), Tesco (TSCO), AstraZeneca (AZN), British American Tobacco (BATS), Cronos Group (CRON), Dairy Crest Group (DCG), Debenhams (DEB), Diageo (DGE) and Experian (EXPN).

How do I buy shares of Genus?

Shares of GNS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:GNS) was last updated on 2/20/2024 by MarketBeat.com Staff